Financings in Brief: Haemonetics
This article was originally published in The Gray Sheet
Executive Summary
Haemonetics: Blood processing system firm's board of directors approves a 1 mil. share repurchase program to buy outstanding shares "at prevailing prices as market conditions warrant." The 1 mil. shares will augment 729,000 shares outstanding already approved for repurchase under a prior plan, the company says. Currently, Haemonetics has 28.8 mil. outstanding shares...